Literature DB >> 8102390

The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.

C McMenamin1, P G Holt.   

Abstract

The immunological basis for atopy is currently ascribed to an inherent bias in the CD4+ T cell response to nonreplicating antigens presented at mucosal surfaces, resulting in dominance of the T helper 2 (Th2) interleukin 4 (IL-4)-producing phenotype, which favors IgE production. In contrast, the "normal" response to such antigens involves a predominance of interferon gamma (IFN-gamma)-producing Th1 clones. This difference has been suggested to be the result of active selection in atopics for Th2 (and hence against Th1) clones at the time of initial antigen presentation. In the study below, we demonstrate that the natural immune response to inhaled protein antigens, particularly in animals expressing the low immunoglobulin E (IgE) responder phenotype, includes a major histocompatibility complex (MHC) class I-restricted CD8+ T cell component, the appearance of which is associated with active suppression of IgE antibody production. Thus, continued exposure of rats to aerosolized ovalbumin (OVA) antigen elicits a transient IgE response, that is terminated by the onset of a state of apparent "tolerance" to further challenge, and this tolerant state is transferable to naive animals with CD8+ T cells. Kinetic studies on in vitro T cell reactivity in these aerosol-exposed rats demonstrated biphasic CD4+ Th2 responses which terminated, together with IgE antibody production, and coincident with the appearance of MHC class I-restricted OVA-specific IFN-gamma-producing CD8+ T cells. However, the latter were not autonomous in vitro and required a source of exogenous IL-2 for initial activation, which in CD(8+)-enriched splenocyte cultures could be provided by small numbers of contaminating OVA-specific CD4+ T cells. This represents the first formal evidence for the induction of an MHC class I-restricted T cell response to natural mucosal exposure to an inert protein antigen, and is consistent with a growing literature demonstrating sensitization of MHC class I-restricted CD8+ T cells by deliberate immunization with soluble proteins. We suggest that crossregulation of MHC class II-restricted CD4+ T cells via cytokine signals generated in parallel CD8+ T cell responses represents a covert and potentially important selection pressure that can shape the nature of host responses to nonreplicating antigens presented at mucosal surfaces.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102390      PMCID: PMC2191183          DOI: 10.1084/jem.178.3.889

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  Induction of IgE-isotype specific tolerance by passive antigenic stimulation of the respiratory mucosa.

Authors:  J D Sedgwick; P G Holt
Journal:  Immunology       Date:  1983-12       Impact factor: 7.397

2.  Suppression of IgE responses in inbred rats by repeated respiratory tract exposure to antigen: responder phenotype influences isotype specificity of induced tolerance.

Authors:  J D Sedgwick; P G Holt
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

3.  T cell synergy in the primary MLR: proliferative kinetics, effector cell generation, and IL 2 production.

Authors:  D R Salomon; D J Cohen; J M Williams; C B Carpenter
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

Review 4.  Functions of rat T-lymphocyte subsets isolated by means of monoclonal antibodies.

Authors:  D W Mason; R P Arthur; M J Dallman; J R Green; G P Spickett; M L Thomas
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

5.  Purification of human C3b inactivator by monoclonal-antibody affinity chromatography.

Authors:  L Hsiung; A N Barclay; M R Brandon; E Sim; R R Porter
Journal:  Biochem J       Date:  1982-04-01       Impact factor: 3.857

6.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

7.  Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.

Authors:  A Miller; O Lider; A B Roberts; M B Sporn; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

8.  Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen.

Authors:  P G Holt; J E Batty; K J Turner
Journal:  Immunology       Date:  1981-03       Impact factor: 7.397

9.  Regulation of T-cell sensitization at epithelial surfaces in the respiratory tract: suppression of IgE responses to inhaled antigens by CD3+ Tcr alpha-/beta- lymphocytes (putative gamma/delta T cells).

Authors:  C McMenamin; J Oliver; B Girn; B J Holt; U R Kees; W R Thomas; P G Holt
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

10.  Antigen-driven bystander suppression after oral administration of antigens.

Authors:  A Miller; O Lider; H L Weiner
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  64 in total

Review 1.  Specificity, restriction and effector mechanisms of immunoregulatory CD8 T cells.

Authors:  M Vukmanovic-Stejic; M J Thomas; A Noble; D M Kemeny
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

2.  Oral administration of antigen does not influence the proliferation and IFN-γ production of responsive CD8+ T cells but enables to establish T cell clones with different lymphokine production profile.

Authors:  K Nishijima; T Hisatsune; H Kato; M Kohyama; M Kakehi; S Hachimura; S Kaminogawa
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

3.  Induction of mucosal tolerance in Peyer's patch-deficient, ligated small bowel loops.

Authors:  Thomas A Kraus; Jens Brimnes; Christine Muong; Jian-Hua Liu; Thomas M Moran; Kelly A Tappenden; Peter Boros; Lloyd Mayer
Journal:  J Clin Invest       Date:  2005-07-21       Impact factor: 14.808

4.  Bystander suppression of the immune response to human serum albumin in rats fed ovalbumin.

Authors:  A Dahlman-Höglund; U Dahlgren; S Ahlstedt; L A Hanson; E Telemo
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 5.  Regulation of IgE production and other immunopathogenetic mechanisms.

Authors:  B A Chowdhury
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

6.  The contrasting effects of CD8+ T cells on primary, established and Nippostrongylus brasiliensis-induced IgE responses.

Authors:  B J Holmes; D Diaz-Sanchez; R A Lawrence; E B Bell; R M Maizels; D M Kemeny
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

Review 7.  Cell and molecular biology of chemical allergy.

Authors:  I Kimber; R J Dearman
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

8.  Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens.

Authors:  R J Dearman; A Moussavi; D M Kemeny; I Kimber
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

9.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major.

Authors:  I Müller; P Kropf; J A Louis; G Milon
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.